Pular para o conteúdo
Anemia de Diamond-Blackfan
ORPHA:124CID-10 · D61.0CID-11 · 3A60.1DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
Sistema ósseoInício neonatalHerança AD
Também conhecida comoPRCADBA
Sinônimos clínicos: PRCA congénita · Anemia congénita pura de células vermelhas · Síndrome de anemia de Diamond-Blackfan

Anemia congênita aregenerativa e frequentemente macrocítica com eritroblastopenia.

Última verificação: Fonte: sem afirmação sobre o SUS a verificarEm construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

💬
EM LINGUAGEM SIMPLES

A anemia de Diamond-Blackfan é um distúrbio que afeta principalmente a medula óssea. Pessoas com essa condição frequentemente também apresentam anomalias físicas que afetam várias partes do corpo.

A principal função da medula óssea é produzir novas células sanguíneas. Na anemia de Diamond-Blackfan, a medula óssea funciona de forma inadequada e deixa de produzir quantidade suficiente de glóbulos vermelhos, que transportam oxigênio para os tecidos do corpo. A escassez resultante de glóbulos vermelhos (anemia) geralmente se torna aparente durante o primeiro ano de vida. Os sintomas da anemia incluem fadiga, fraqueza e uma aparência anormalmente pálida (palidez).

Pessoas com anemia de Diamond-Blackfan têm risco aumentado de várias complicações graves relacionadas à sua medula óssea disfuncional. Especificamente, elas têm uma chance maior que a média de desenvolver síndrome mielodisplásica (MDS), que é um distúrbio no qual as células sanguíneas imaturas não se desenvolvem normalmente. Indivíduos com anemia de Diamond-Blackfan também têm risco aumentado de desenvolver um câncer da medula óssea conhecido como leucemia mieloide aguda (LMA), um tipo de câncer ósseo chamado osteossarcoma e outros cânceres.

Aproximadamente metade dos indivíduos com anemia de Diamond-Blackfan apresentam anomalias físicas. Eles podem ter um tamanho de cabeça incomumente pequeno (microcefalia) e uma linha capilar frontal baixa, juntamente com características faciais distintas, como olhos afastados (hipertelorismo); pálpebras caídas (ptose); uma ponte do nariz larga e plana; orelhas pequenas e baixas; e um queixo inferior pequeno (micrognatia). Os indivíduos afetados também podem ter uma abertura no palato (fenda palatina) com ou sem fissura no lábio superior (fenda labial). Eles podem ter um pescoço curto e webado; escápulas menores e mais altas que o usual; e anomalias nas mãos, sendo mais comum polegares malformados ou ausentes. Cerca de um terço dos indivíduos afetados apresentam crescimento lento que leva a baixa estatura.

Outras características da anemia de Diamond-Blackfan podem incluir problemas oculares, como opacificação da lente dos olhos (catarata), aumento da pressão intraocular (glaucoma) ou olhos que não se alinham na mesma direção (estrabismo). Os indivíduos afetados também podem apresentar anomalias renais; defeitos estruturais do coração; e, nos homens, a abertura da uretra na parte inferior do pênis (hipospadia).

A gravidade da anemia de Diamond-Blackfan pode variar, mesmo dentro da mesma família. Cada vez mais, indivíduos com anemia de Diamond-Blackfan “não clássica” têm sido identificados. Essa forma do distúrbio tipicamente apresenta sintomas menos graves. Por exemplo, alguns indivíduos afetados têm anemia leve que começa mais tarde na infância ou na idade adulta, enquanto outros apresentam algumas das características físicas, mas sem problemas na medula óssea.

Fonte: MedlinePlus Genetics (NLM/NIH), traduzido
📋
Informacoes curadas por IA — podem conter imprecisoes

Anemia congênita aregenerativa e frequentemente macrocítica com eritroblastopenia.

Pesquisas ativas
10 ensaios
53 total registrados no ClinicalTrials.gov
Publicações científicas
862 artigos
Último publicado: 2026 Apr
Medicamentos
19 com registro
FILGRASTIM, FIPRIMA, ZARZIO

Tem tratamento?

✓ 19 medicamentos específicos desta doença (registro ANVISA, FDA ou SUS/CEAF)
Ver detalhes, fases e interações →
FILGRASTIMFIPRIMAZARZIOGRANULOKINEFILGRASTINEFILAZACITIDINAXPREZA
Mais 9 moléculas em estudo para esta doença.

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
Childhood
+ infancy, neonatal
🏥
SUS: Cobertura mínimaScore: 0%
CID-10: D61.0
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🦴
Ossos e articulações
26 sintomas
😀
Face
19 sintomas
❤️
Coração
11 sintomas
🩸
Sangue
11 sintomas
👂
Ouvidos
10 sintomas
👁️
Olhos
8 sintomas

+ 55 sintomas em outras categorias

Características mais comuns

90%prev.
Aplasia pura de células vermelhas
Muito frequente (99-80%)
90%prev.
Atividade elevada da adenosina desaminase eritrocitária
Muito frequente (99-80%)
55%prev.
Atraso de crescimento
Frequente (79-30%)
55%prev.
Anemia diseritropoiética macrocítica
Frequente (79-30%)
55%prev.
Hipoplasia eritroide
Frequente (79-30%)
55%prev.
Persistência de hemoglobina F
Frequente (79-30%)
179sintomas
Muito frequente (2)
Frequente (10)
Ocasional (25)
Muito raro (22)
Sem dados (120)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 179 características clínicas mais associadas, ordenadas por frequência.

Muito frequente (99-80%)90%
Atividade elevada da adenosina desaminase eritrocitáriaElevated red cell adenosine deaminase activity
Muito frequente (99-80%)90%
Frequente (79-30%)55%
Anemia diseritropoiética macrocíticaMacrocytic dyserythropoietic anemia
Frequente (79-30%)55%
Hipoplasia eritroideErythroid hypoplasia
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico862PubMed
Últimos 10 anos9publicações
Pico20214 papers
Linha do tempo
2026Hoje · 2026🧪 1994Primeiro ensaio clínico📈 2021Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

26 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant.

Curadoria gene-doença

fontes oficiais
RPS19 RPS10 RPS24GATA1HEATR3
RPS19 RPS10 RPS24
RPL18Large ribosomal subunit protein eL18Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsRibosome Quality Control (RQC) complex extracts and degrades nascent peptideMajor pathway of rRNA processing in the nucleolus and cytosolGTP hydrolysis and joining of the 60S ribosomal subunitL13a-mediated translational silencing of Ceruloplasmin expression
MECANISMO DE DOENÇA

Diamond-Blackfan anemia 18

A form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of malignancy. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies. DBA18 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
2269.1 TPM
Linfócitos
1309.3 TPM
Skin Sun Exposed Lower leg
1257.9 TPM
Skin Not Sun Exposed Suprapubic
1250.3 TPM
Cervix Ectocervix
1238.0 TPM
OUTRAS DOENÇAS (2)
Diamond-Blackfan anemia 18Diamond-Blackfan anemia
HGNC:10310UniProt:Q07020
RPL8Large ribosomal subunit protein uL2Disease-causing germline mutation(s) (loss of function) inDesconhecido
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsRibosome Quality Control (RQC) complex extracts and degrades nascent peptideMajor pathway of rRNA processing in the nucleolus and cytosolGTP hydrolysis and joining of the 60S ribosomal subunitL13a-mediated translational silencing of Ceruloplasmin expression
EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
3861.7 TPM
Linfócitos
2796.7 TPM
Cervix Ectocervix
2570.8 TPM
Skin Not Sun Exposed Suprapubic
2459.7 TPM
Cervix Endocervix
2437.5 TPM
OUTRAS DOENÇAS (1)
Diamond-Blackfan anemia
HGNC:10368UniProt:P62917
ADA2Adenosine deaminase 2Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
Neutrophil degranulationSurfactant metabolism
MECANISMO DE DOENÇA

Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome

An autosomal recessive, systemic necrotizing vasculitis that affects medium and small arteries. The ensuing tissue ischemia can affect any organ, including the skin, musculoskeletal system, kidneys, gastrointestinal tract, and the cardiovascular and nervous systems. Organ involvement and disease severity are highly variable. Clinical features include recurrent ischemic stroke affecting the small vessels of the brain and resulting in neurologic dysfunction, recurrent fever, myalgias, livedoid rash, gastrointestinal pain and hepatosplenomegaly.

OUTRAS DOENÇAS (3)
vasculitis due to ADA2 deficiencySneddon syndromeDiamond-Blackfan anemia
HGNC:1839UniProt:Q9NZK5
RPS10Small ribosomal subunit protein eS10Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsMajor pathway of rRNA processing in the nucleolus and cytosolSARS-CoV-2 modulates host translation machinerySARS-CoV-1 modulates host translation machineryViral mRNA Translation
MECANISMO DE DOENÇA

Diamond-Blackfan anemia 9

An autosomal dominant form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of malignancy. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
1681.1 TPM
Linfócitos
1474.9 TPM
Fibroblastos
1208.3 TPM
Cervix Ectocervix
1176.5 TPM
Cervix Endocervix
1060.4 TPM
OUTRAS DOENÇAS (2)
Diamond-Blackfan anemia 9Diamond-Blackfan anemia
HGNC:10383UniProt:P46783
RPL35ALarge ribosomal subunit protein eL33Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsRibosome Quality Control (RQC) complex extracts and degrades nascent peptideMajor pathway of rRNA processing in the nucleolus and cytosolGTP hydrolysis and joining of the 60S ribosomal subunitL13a-mediated translational silencing of Ceruloplasmin expression
MECANISMO DE DOENÇA

Diamond-Blackfan anemia 5

An autosomal dominant form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of malignancy. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
1291.9 TPM
Cervix Endocervix
814.4 TPM
Linfócitos
811.9 TPM
Cervix Ectocervix
777.8 TPM
Útero
683.3 TPM
OUTRAS DOENÇAS (2)
Diamond-Blackfan anemia 5Diamond-Blackfan anemia
HGNC:10345UniProt:P18077
RPS29Small ribosomal subunit protein uS14Disease-causing germline mutation(s) (loss of function) inDesconhecido
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsMajor pathway of rRNA processing in the nucleolus and cytosolSARS-CoV-2 modulates host translation machinerySARS-CoV-1 modulates host translation machineryViral mRNA Translation
MECANISMO DE DOENÇA

Diamond-Blackfan anemia 13

An autosomal dominant form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of malignancy. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
176.7 TPM
Ovário
147.4 TPM
Fibroblastos
114.4 TPM
Skin Sun Exposed Lower leg
107.2 TPM
Cervix Ectocervix
104.8 TPM
OUTRAS DOENÇAS (2)
Diamond-Blackfan anemia 13Diamond-Blackfan anemia
HGNC:10419UniProt:P62273
RPS19Small ribosomal subunit protein eS19Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsMajor pathway of rRNA processing in the nucleolus and cytosolSARS-CoV-2 modulates host translation machinerySARS-CoV-1 modulates host translation machineryViral mRNA Translation
MECANISMO DE DOENÇA

Diamond-Blackfan anemia 1

An autosomal dominant form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of developing leukemia. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
934.3 TPM
Ovário
836.5 TPM
Fibroblastos
780.7 TPM
Skin Sun Exposed Lower leg
685.7 TPM
Skin Not Sun Exposed Suprapubic
670.9 TPM
OUTRAS DOENÇAS (2)
Diamond-Blackfan anemia 1Diamond-Blackfan anemia
HGNC:10402UniProt:P39019
RPS28Small ribosomal subunit protein eS28Disease-causing germline mutation(s) (loss of function) inRestrito
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsMajor pathway of rRNA processing in the nucleolus and cytosolSARS-CoV-2 modulates host translation machinerySARS-CoV-1 modulates host translation machineryViral mRNA Translation
MECANISMO DE DOENÇA

Diamond-Blackfan anemia 15, with mandibulofacial dysostosis

An autosomal dominant form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of malignancy. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
1185.5 TPM
Linfócitos
1182.7 TPM
Skin Not Sun Exposed Suprapubic
999.4 TPM
Skin Sun Exposed Lower leg
975.0 TPM
Fibroblastos
896.5 TPM
OUTRAS DOENÇAS (2)
Diamond-Blackfan anemia 15 with mandibulofacial dysostosisDiamond-Blackfan anemia
HGNC:10418UniProt:P62857
RPS24Small ribosomal subunit protein eS24Disease-causing germline mutation(s) inDesconhecido
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsMajor pathway of rRNA processing in the nucleolus and cytosolSARS-CoV-2 modulates host translation machinerySARS-CoV-1 modulates host translation machineryViral mRNA Translation
MECANISMO DE DOENÇA

Diamond-Blackfan anemia 3

An autosomal dominant form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of developing leukemia. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
1214.1 TPM
Linfócitos
881.7 TPM
Cervix Endocervix
794.4 TPM
Cervix Ectocervix
793.9 TPM
Fibroblastos
734.1 TPM
OUTRAS DOENÇAS (2)
Diamond-Blackfan anemia 3Diamond-Blackfan anemia
HGNC:10411UniProt:P62847
RPL31Large ribosomal subunit protein eL31Candidate gene tested inDesconhecido
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsRibosome Quality Control (RQC) complex extracts and degrades nascent peptideMajor pathway of rRNA processing in the nucleolus and cytosolGTP hydrolysis and joining of the 60S ribosomal subunitL13a-mediated translational silencing of Ceruloplasmin expression
EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
655.5 TPM
Linfócitos
513.6 TPM
Cervix Endocervix
414.7 TPM
Cervix Ectocervix
411.9 TPM
Fibroblastos
375.6 TPM
OUTRAS DOENÇAS (1)
Diamond-Blackfan anemia
HGNC:10334UniProt:P62899
RPL11Large ribosomal subunit protein uL5Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsRibosome Quality Control (RQC) complex extracts and degrades nascent peptideMajor pathway of rRNA processing in the nucleolus and cytosolGTP hydrolysis and joining of the 60S ribosomal subunitL13a-mediated translational silencing of Ceruloplasmin expression
MECANISMO DE DOENÇA

Diamond-Blackfan anemia 7

An autosomal dominant form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of malignancy. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
1874.9 TPM
Linfócitos
1495.0 TPM
Cervix Ectocervix
1222.1 TPM
Fibroblastos
1192.8 TPM
Cervix Endocervix
1160.8 TPM
OUTRAS DOENÇAS (2)
Diamond-Blackfan anemia 7Diamond-Blackfan anemia
HGNC:10301UniProt:P62913
RPL9Large ribosomal subunit protein uL6Disease-causing germline mutation(s) inDesconhecido
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsRibosome Quality Control (RQC) complex extracts and degrades nascent peptideMajor pathway of rRNA processing in the nucleolus and cytosolGTP hydrolysis and joining of the 60S ribosomal subunitL13a-mediated translational silencing of Ceruloplasmin expression
EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
4476.5 TPM
Linfócitos
2950.8 TPM
Cervix Ectocervix
2614.7 TPM
Cervix Endocervix
2528.6 TPM
Útero
2398.1 TPM
OUTRAS DOENÇAS (1)
Diamond-Blackfan anemia
HGNC:10369UniProt:P32969
GATA1Erythroid transcription factorDisease-causing germline mutation(s) (loss of function) inAltamente restrito
VIAS BIOLÓGICAS (3)
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet functionRUNX1 regulates transcription of genes involved in differentiation of HSCsFactors involved in megakaryocyte development and platelet production
MECANISMO DE DOENÇA

X-linked dyserythropoietic anemia and thrombocytopenia

Disorder characterized by erythrocytes with abnormal size and shape, and paucity of platelets in peripheral blood. The bone marrow contains abundant and abnormally small megakaryocytes.

EXPRESSÃO TECIDUAL(Tecido-específico)
Sangue
25.8 TPM
Pulmão
3.7 TPM
Testículo
3.6 TPM
Baço
1.9 TPM
Pituitária
0.8 TPM
OUTRAS DOENÇAS (10)
transient myeloproliferative syndromethrombocytopenia, X-linked, with or without dyserythropoietic anemiahemolytic anemia due to erythrocyte adenosine deaminase overproductionX-linked dyserythropoetic anemia with abnormal platelets and neutropenia
HGNC:4170UniProt:P15976
RPL26Large ribosomal subunit protein uL24Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsRibosome Quality Control (RQC) complex extracts and degrades nascent peptideMajor pathway of rRNA processing in the nucleolus and cytosolGTP hydrolysis and joining of the 60S ribosomal subunitL13a-mediated translational silencing of Ceruloplasmin expression
MECANISMO DE DOENÇA

Diamond-Blackfan anemia 11

An autosomal dominant form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of malignancy. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
1462.9 TPM
Ovário
1410.2 TPM
Fibroblastos
997.2 TPM
Cervix Ectocervix
905.0 TPM
Cervix Endocervix
899.9 TPM
OUTRAS DOENÇAS (2)
Diamond-Blackfan anemia 11Diamond-Blackfan anemia
HGNC:10327UniProt:P61254
RPL35Large ribosomal subunit protein uL29Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsRibosome Quality Control (RQC) complex extracts and degrades nascent peptideMajor pathway of rRNA processing in the nucleolus and cytosolGTP hydrolysis and joining of the 60S ribosomal subunitL13a-mediated translational silencing of Ceruloplasmin expression
MECANISMO DE DOENÇA

Diamond-Blackfan anemia 19

A form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of malignancy. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies. DBA19 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
2429.0 TPM
Ovário
2365.1 TPM
Skin Not Sun Exposed Suprapubic
1898.6 TPM
Skin Sun Exposed Lower leg
1815.1 TPM
Cervix Ectocervix
1813.0 TPM
OUTRAS DOENÇAS (2)
Diamond-Blackfan anemia 19Diamond-Blackfan anemia
HGNC:10344UniProt:P42766
RPS20Small ribosomal subunit protein uS10Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsMajor pathway of rRNA processing in the nucleolus and cytosolSARS-CoV-2 modulates host translation machinerySARS-CoV-1 modulates host translation machineryViral mRNA Translation
EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
1353.5 TPM
Linfócitos
957.4 TPM
Cervix Ectocervix
885.0 TPM
Cervix Endocervix
834.7 TPM
Tecido adiposo
749.1 TPM
OUTRAS DOENÇAS (2)
familial colorectal cancer type XDiamond-Blackfan anemia
HGNC:10405UniProt:P60866
RPL15Large ribosomal subunit protein eL15Disease-causing germline mutation(s) inDesconhecido
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsRibosome Quality Control (RQC) complex extracts and degrades nascent peptideMajor pathway of rRNA processing in the nucleolus and cytosolGTP hydrolysis and joining of the 60S ribosomal subunitL13a-mediated translational silencing of Ceruloplasmin expression
MECANISMO DE DOENÇA

Diamond-Blackfan anemia 12

An autosomal dominant form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of malignancy. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
907.0 TPM
Cervix Endocervix
635.4 TPM
Linfócitos
622.4 TPM
Cervix Ectocervix
616.6 TPM
Útero
582.7 TPM
OUTRAS DOENÇAS (2)
Diamond-Blackfan anemia 12Diamond-Blackfan anemia
HGNC:10306UniProt:P61313
HEATR3HEAT repeat-containing protein 3Disease-causing germline mutation(s) inTolerante
MECANISMO DE DOENÇA

Diamond-Blackfan anemia 21

An autosomal recessive form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of malignancy. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies. DBA21 patients manifest bone marrow failure, short stature, facial and acromelic dysmorphic features, and intellectual disability.

EXPRESSÃO TECIDUAL(Ubíquo)
Baço
23.9 TPM
Cérebro - Hemisfério cerebelar
23.3 TPM
Cerebelo
20.2 TPM
Fibroblastos
18.8 TPM
Linfócitos
16.9 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (2)
Diamond-Blackfan anemia 21Diamond-Blackfan anemia
HGNC:26087UniProt:Q7Z4Q2
RPL5Large ribosomal subunit protein uL18Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsRibosome Quality Control (RQC) complex extracts and degrades nascent peptideMajor pathway of rRNA processing in the nucleolus and cytosolGTP hydrolysis and joining of the 60S ribosomal subunitL13a-mediated translational silencing of Ceruloplasmin expression
MECANISMO DE DOENÇA

Diamond-Blackfan anemia 6

An autosomal dominant form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of malignancy. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
4772.8 TPM
Linfócitos
2937.8 TPM
Cervix Ectocervix
2573.5 TPM
Cervix Endocervix
2553.4 TPM
Útero
2508.4 TPM
OUTRAS DOENÇAS (2)
Diamond-Blackfan anemia 6Diamond-Blackfan anemia
HGNC:10360UniProt:P46777
RPS15ASmall ribosomal subunit protein uS8Disease-causing germline mutation(s) (loss of function) inDesconhecido
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsMajor pathway of rRNA processing in the nucleolus and cytosolSARS-CoV-2 modulates host translation machinerySARS-CoV-1 modulates host translation machineryViral mRNA Translation
MECANISMO DE DOENÇA

Diamond-Blackfan anemia 20

A form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of malignancy. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies. DBA20 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
439.4 TPM
Linfócitos
414.4 TPM
Cervix Ectocervix
296.5 TPM
Cervix Endocervix
279.4 TPM
Fibroblastos
273.0 TPM
OUTRAS DOENÇAS (2)
Diamond-Blackfan anemia 20Diamond-Blackfan anemia
HGNC:10389UniProt:P62244
RPS17Small ribosomal subunit protein eS17Disease-causing germline mutation(s) inDesconhecido
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsMajor pathway of rRNA processing in the nucleolus and cytosolSARS-CoV-2 modulates host translation machinerySARS-CoV-1 modulates host translation machineryViral mRNA Translation
MECANISMO DE DOENÇA

Diamond-Blackfan anemia 4

An autosomal dominant form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of developing leukemia. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
1429.7 TPM
Ovário
1346.7 TPM
Fibroblastos
1110.5 TPM
Skin Not Sun Exposed Suprapubic
923.2 TPM
Cervix Ectocervix
921.4 TPM
OUTRAS DOENÇAS (2)
Diamond-Blackfan anemia 4Diamond-Blackfan anemia
HGNC:10397UniProt:P08708
RPL27Large ribosomal subunit protein eL27Candidate gene tested inDesconhecido
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsRibosome Quality Control (RQC) complex extracts and degrades nascent peptideMajor pathway of rRNA processing in the nucleolus and cytosolGTP hydrolysis and joining of the 60S ribosomal subunitL13a-mediated translational silencing of Ceruloplasmin expression
MECANISMO DE DOENÇA

Diamond-Blackfan anemia 16

An autosomal dominant form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of malignancy. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
1721.7 TPM
Fibroblastos
1484.6 TPM
Ovário
1462.1 TPM
Cervix Ectocervix
1216.0 TPM
Skin Not Sun Exposed Suprapubic
1200.2 TPM
OUTRAS DOENÇAS (2)
Diamond-Blackfan anemia 16Diamond-Blackfan anemia
HGNC:10328UniProt:P61353
RPS7Small ribosomal subunit protein eS7Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsMajor pathway of rRNA processing in the nucleolus and cytosolSARS-CoV-2 modulates host translation machinerySARS-CoV-1 modulates host translation machineryViral mRNA Translation
MECANISMO DE DOENÇA

Diamond-Blackfan anemia 8

An autosomal dominant form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of malignancy. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
2452.2 TPM
Linfócitos
2265.7 TPM
Fibroblastos
1584.8 TPM
Skin Not Sun Exposed Suprapubic
1292.2 TPM
Cervix Ectocervix
1262.9 TPM
OUTRAS DOENÇAS (2)
Diamond-Blackfan anemia 8Diamond-Blackfan anemia
HGNC:10440UniProt:P62081
RPS26Small ribosomal subunit protein eS26Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsMajor pathway of rRNA processing in the nucleolus and cytosolSARS-CoV-2 modulates host translation machinerySARS-CoV-1 modulates host translation machineryViral mRNA Translation
MECANISMO DE DOENÇA

Diamond-Blackfan anemia 10

An autosomal dominant form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of malignancy. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
688.3 TPM
Ovário
658.3 TPM
Cervix Endocervix
524.3 TPM
Fibroblastos
495.1 TPM
Glândula adrenal
446.2 TPM
OUTRAS DOENÇAS (2)
Diamond-Blackfan anemia 10Diamond-Blackfan anemia
HGNC:10414UniProt:P62854
RPS27Small ribosomal subunit protein eS27Candidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (10)
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signalRHO GTPases Activate ForminsMitotic PrometaphaseEML4 and NUDC in mitotic spindle formationResolution of Sister Chromatid Cohesion
MECANISMO DE DOENÇA

Diamond-Blackfan anemia 17

An autosomal dominant form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of malignancy. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
4528.6 TPM
Cervix Endocervix
2936.8 TPM
Linfócitos
2822.3 TPM
Cervix Ectocervix
2812.5 TPM
Fallopian Tube
2427.5 TPM
OUTRAS DOENÇAS (2)
Diamond-Blackfan anemia 17Diamond-Blackfan anemia
HGNC:10416UniProt:P42677
TSR2Pre-rRNA-processing protein TSR2 homologDisease-causing germline mutation(s) (loss of function) inAltamente restrito
MECANISMO DE DOENÇA

Diamond-Blackfan anemia 14, with mandibulofacial dysostosis

An X-linked recessive form of Diamond-Blackfan anemia, a congenital non-regenerative hypoplastic anemia that usually presents early in infancy. Diamond-Blackfan anemia is characterized by a moderate to severe macrocytic anemia, erythroblastopenia, and an increased risk of malignancy. 30 to 40% of Diamond-Blackfan anemia patients present with short stature and congenital anomalies, the most frequent being craniofacial (Pierre-Robin syndrome and cleft palate), thumb and urogenital anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
201.1 TPM
Brain Frontal Cortex BA9
166.3 TPM
Brain Nucleus accumbens basal ganglia
142.2 TPM
Hipotálamo
141.8 TPM
Substância negra
140.9 TPM
OUTRAS DOENÇAS (2)
Diamond-Blackfan anemia 14 with mandibulofacial dysostosisDiamond-Blackfan anemia
HGNC:25455UniProt:Q969E8

Medicamentos e terapias

FLUDARABINE PHOSPHATEPhase 2

Mecanismo: DNA polymerase (alpha/delta/epsilon) inhibitor

DACLIZUMABPhase 2

Mecanismo: Interleukin-2 receptor inhibitor

MYCOPHENOLATE MOFETILPhase 2

Mecanismo: Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor

TACROLIMUS ANHYDROUSPhase 2

Mecanismo: FK506-binding protein 1A inhibitor

FILGRASTIMPhase 2

Mecanismo: Granulocyte colony stimulating factor receptor agonist

METHOTREXATEPhase 2

Mecanismo: Dihydrofolate reductase inhibitor

SOTATERCEPTPhase 1

Mecanismo: Inhibin beta A chain inhibitor

TRIFLUOPERAZINEPhase 1

Mecanismo: Serotonin 2c (5-HT2c) receptor antagonist

BITOPERTINPhase 1

Mecanismo: Glycine transporter 1 inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

700 variantes patogênicas registradas no ClinVar.

🧬 RPL18: NM_000979.4(RPL18):c.421+21G>A ()
🧬 RPL18: GRCh37/hg19 19q13.33(chr19:49088521-50423301)x3 ()
🧬 RPL18: NM_000979.4(RPL18):c.397G>C (p.Gly133Arg) ()
🧬 RPL18: GRCh37/hg19 19q13.33-13.41(chr19:48905537-51614930)x3 ()
🧬 RPL18: NM_000979.4(RPL18):c.181C>G (p.Leu61Val) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 2.154 variantes classificadas pelo ClinVar.

1077
1077
VUS (50.0%)
Benigna (50.0%)
VARIANTES MAIS SIGNIFICATIVAS
DRC9: NM_000996.4(RPL35A):c.50G>C (p.Gly17Ala) [Uncertain significance]
RPS19: NM_001022.4(RPS19):c.5C>T (p.Pro2Leu) [Uncertain significance]
RPS26: NM_001029.5(RPS26):c.82C>G (p.Arg28Gly) [Uncertain significance]
RPS19: NM_001022.4(RPS19):c.59C>T (p.Ala20Val) [Uncertain significance]
RPS24: NM_033022.4(RPS24):c.140T>C (p.Met47Thr) [Uncertain significance]

Vias biológicas (Reactome)

35 vias biológicas associadas aos genes desta condição.

L13a-mediated translational silencing of Ceruloplasmin expression Peptide chain elongation SRP-dependent cotranslational protein targeting to membrane Viral mRNA Translation Selenocysteine synthesis Major pathway of rRNA processing in the nucleolus and cytosol Formation of a pool of free 40S subunits GTP hydrolysis and joining of the 60S ribosomal subunit Eukaryotic Translation Termination Regulation of expression of SLITs and ROBOs Response of EIF2AK4 (GCN2) to amino acid deficiency Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) Dengue Virus-Host Interactions Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA Protein hydroxylation Surfactant metabolism Neutrophil degranulation Translation initiation complex formation Formation of the ternary complex, and subsequently, the 43S complex Ribosomal scanning and start codon recognition SARS-CoV-1 modulates host translation machinery SARS-CoV-2 modulates host translation machinery RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function RUNX1 regulates transcription of genes involved in differentiation of HSCs Factors involved in megakaryocyte development and platelet production rRNA modification in the nucleus and cytosol Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion RHO GTPases Activate Formins Mitotic Prometaphase EML4 and NUDC in mitotic spindle formation

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
✓Aprovado1
3Fase 34
2Fase 235
1Fase 18
·Pré-clínico14
Medicamentos catalogadosEnsaios clínicos· 9 medicamentos · 53 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Anemia de Diamond-Blackfan

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 3 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

9 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

53 ensaios clínicos encontrados, 10 ativos.

Distribuição por fase
NCT01966367 · CD34+ (Non-Malignant) Stem Cell Selection for Patients Recei…Ativo
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT05828108 · Study of the Selective GlyT1 Inhibitor Bitopertin for Steroi…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT04965597 · Treosulfan-Based Conditioning Regimen Before a Blood or Bone…Concluído
PHASE2🇺🇸 Estados Unidos
NCT04269889 · Treatment of Refractory Diamond-Blackfan Anemia With Eltromb…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT03513328 · Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell …Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT01917708 · Bone Marrow Transplant With Abatacept for Non-Malignant Dise…Concluído
PHASE1🇺🇸 Estados Unidos
NCT01362595 · Pilot Phase I/II Study of Amino Acid Leucine in Treatment of…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT01586455 · Human Placental-Derived Stem Cell TransplantationConcluído
PHASE1🇺🇸 Estados Unidos
NCT01758042 · Bone Marrow and Kidney Transplant for Patients With Chronic …Concluído
NA🇺🇸 Estados Unidos
NCT01913548 · Multi-Center Study of Iron Overload: Survey Study (MCSIO)Concluído
🇩🇪 Alemanha · 🇬🇧 Reino Unido · 🇺🇸 Estados Unidos
NCT01114776 · Multi-Center Study of Iron Overload: Pilot StudyConcluído
🇩🇪 Alemanha · 🇬🇧 Reino Unido · 🇺🇸 Estados Unidos
NCT00919503 · Treosulfan and Fludarabine Phosphate Before Donor Stem Cell …Concluído
PHASE2🇺🇸 Estados Unidos
NCT00957931 · Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorder…Concluído
PHASE2🇺🇸 Estados Unidos
NCT00744692 · Reduced Intensity Conditioning for Umbilical Cord Blood Tran…Concluído
PHASE1🇺🇸 Estados Unidos
NCT00600938 · Evaluating Use of Deferasirox as Compared to Deferoxamine in…Concluído
PHASE2🇨🇦 Canadá · 🇨🇳 China · Cyprus +8
NCT00673608 · Magnetic Resonance Imaging (MRI) Assessments of the Heart an…Concluído
PHASE4🇦🇺 Austrália
NCT00244010 · Partially Matched Stem Cell Transplantation for Patients Wit…Concluído
NA🇺🇸 Estados Unidos
NCT00235391 · Expanded Access of Deferasirox to Patients With Congenital D…Concluído
PHASE3🇧🇪 Bélgica · 🇨🇦 Canadá · 🇩🇪 Alemanha +9
NCT00229619 · Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell A…Concluído
PHASE2🇺🇸 Estados Unidos
NCT00171821 · A Study Assessing the Efficacy and Safety of Deferasirox in …Concluído
PHASE3🇦🇺 Austrália · 🇦🇹 Áustria · 🇧🇪 Bélgica +20
NCT00301834 · Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Ste…Concluído
PHASE2🇺🇸 Estados Unidos
NCT01044186 · A Protocol to Allow Treatment With ICL670 for Patients With …Concluído
PHASE2Greece · 🇮🇹 Itália · 🇺🇸 Estados Unidos
NCT00061763 · Study of Deferasirox in Iron Overload From Beta-thalassemia …Concluído
PHASE2🇺🇸 Estados Unidos
NCT00176852 · Stem Cell Transplant for HemoglobinopathyConcluído
PHASE2, PHASE3🇺🇸 Estados Unidos
NCT00011505 · Mobilization of Stem Cells With G-CSF for Collection From Pa…Concluído
PHASE2🇺🇸 Estados Unidos
NCT00305708 · Busulfan, Antithymocyte Globulin, and Fludarabine Followed B…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT00176878 · Stem Cell Transplant for Bone Marrow Failure SyndromesConcluído
PHASE2, PHASE3🇺🇸 Estados Unidos
NCT00005893 · Study of Allogeneic Bone Marrow Transplantation Using Matche…Concluído
NA🇺🇸 Estados Unidos
NCT00001749 · Medical Treatment for Diamond Blackfan AnemiaConcluído
PHASE2🇺🇸 Estados Unidos
NCT00004378 · Stem Cell Transplantation (SCT) for Genetic DiseasesConcluído
NA🇺🇸 Estados Unidos
NCT00578435 · Allogeneic Bone Marrow Transplantation for the Treatment of …Concluído
PHASE2🇺🇸 Estados Unidos
NCT02386267 · L-leucine in Diamond Blackfan Anemia PatientsUNKNOWN
PHASE2Russia
NCT02061800 · CD34+ (Malignant) Stem Cell Selection for Patients Receiving…UNKNOWN
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT03966053 · The Use of Trifluoperazine in Transfusion Dependent DBAEncerrado
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT03733249 · Long Term Follow-up Study for Patients Enrolled on the BP-00…Encerrado
PHASE1, PHASE2🇮🇹 Itália
NCT02231710 · Safety Study of Gene Modified Donor T Cell Infusion After St…Encerrado
PHASE1🇺🇸 Estados Unidos
NCT02179359 · Hematopoietic Stem Cell Transplant for High Risk Hemoglobino…Encerrado
NA🇺🇸 Estados Unidos
NCT02065869 · Safety Study of Gene Modified Donor T-cells Following TCRαβ+…Encerrado
PHASE1, PHASE2🇮🇹 Itália · 🇬🇧 Reino Unido
NCT01464164 · Safety and Efficacy Study of Sotatercept in Adults With Tran…Encerrado
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT01319851 · Alefacept and Allogeneic Hematopoietic Stem Cell Transplanta…Encerrado
NA🇺🇸 Estados Unidos
NCT02512679 · Related Hematopoietic Stem Cell Transplantation (HSCT) for G…Encerrado
PHASE2
NCT00001962 · A Study to Determine Whether Therapy With Daclizumab Will Be…Encerrado
PHASE2🇺🇸 Estados Unidos
NCT00290628 · Donor Umbilical Cord Blood Transplant in Treating Patients W…Encerrado
NA🇺🇸 Estados Unidos
NCT01419704 · Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobi…Cancelado
PHASE1, PHASE2🇺🇸 Estados Unidos
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
429 papers (10 anos)

Mostrando amostra de 9 publicações de um total de 429

#1

Congenital pure red cell anemia and idiopathic very early onset of severe colitis cured by allogeneic hematopoetic stem cell transplantation.

Pediatric blood &amp; cancer2023 Nov
#2

[Advances in bone marrow failure related ribosomopathies].

Zhonghua er ke za zhi = Chinese journal of pediatrics2021 Sep 02

由机体核糖体合成或功能障碍所导致的一组疾病称为核糖体病,多数为遗传性罕见病。其中,以造血衰竭为主要表现的核糖体病主要包括先天性纯红细胞再生障碍性贫血(Diamond-Blackfan anemia,DBA)、舒-戴综合征(Shwachma-Diamond syndrome,SDS)以及部分先天性角化不良(congenital dyskeratosis,DC)。由于该类疾病发病率低,临床异质性大,我国医师对其认识不够充分,此类疾病常被误诊、漏诊。本文从发病机制、临床特点及诊疗手段的角度,对核糖体异常相关造血衰竭疾病进行综述。.

#3

Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemia.

Science translational medicine2021 Sep 08

Ribosome dysfunction underlies the pathogenesis of many cancers and heritable ribosomopathies. Here, we investigate how mutations in either ribosomal protein large (RPL) or ribosomal protein small (RPS) subunit genes selectively affect erythroid progenitor development and clinical phenotypes in Diamond-Blackfan anemia (DBA), a rare ribosomopathy with limited therapeutic options. Using single-cell assays of patient-derived bone marrow, we delineated two distinct cellular trajectories segregating with ribosomal protein genotypes. Almost complete loss of erythroid specification was observed in RPS-DBA. In contrast, we observed relative preservation of qualitatively abnormal erythroid progenitors and precursors in RPL-DBA. Although both DBA genotypes exhibited a proinflammatory bone marrow milieu, RPS-DBA was characterized by erythroid differentiation arrest, whereas RPL-DBA was characterized by preserved GATA1 expression and activity. Compensatory stress erythropoiesis in RPL-DBA exhibited disordered differentiation underpinned by an altered glucocorticoid molecular signature, including reduced ZFP36L2 expression, leading to milder anemia and improved corticosteroid response. This integrative analysis approach identified distinct pathways of erythroid failure and defined genotype-phenotype correlations in DBA. These findings may help facilitate therapeutic target discovery.

#4

[Research Progress on Pathogenesis of Congenital Pure Red Cell Aplasia---Review].

Zhongguo shi yan xue ye xue za zhi2021 Oct

Congenital pure red cell aplasia, also known as Diamond-Blackfan anemia (DBA), is a hereditary disease characterized by pure red cell aplasia and congenital malformation. Its main clinical features are anemia, dysplasia, and tumor susceptibility. Ribosomal protein (RP) gene mutation is the main pathogenesis of DBA. The most common type of gene mutation is RPS19 gene mutation. Heterozygous mutations in as many as 19 RP genes and other non-RP genes mutations have been identified in DBA. This review summarized briedfly the latest research advances in the pathogenesis of DBA. 先天性纯红细胞再生障碍性贫血发病机制的研究进展. 先天性纯红细胞再生障碍又名Diamond-Blackfan贫血(DBA),是以单纯红系再生障碍和先天性畸形为特征的遗传性疾病,以贫血、身体发育异常和肿瘤易感性为主要临床特征。核糖体蛋白质(RP)基因突变是DBA的主要发病机制,最常见的基因突变类型为RPS19基因突变,目前已在DBA患者中发现了19个RP基因的杂合突变及其他非RP基因的突变。本文对基因突变引起DBA的最新研究进展进行综述。.

#5

Pearson syndrome in a child transplanted for Diamond-Blackfan anemia.

Archivos argentinos de pediatria2021 Oct

Pearson syndrome (PS), shares a number of overlapping features with Diamond-Blackfan anemia (DBA), including early onset of severe anemia, making differential diagnosis important. Differential diagnosis of DBA and PS is critical, since those with DBA may respond to treatment with steroids, may undergo remission, or may benefit from hematopoietic stem cell transplantation (HSCT). However, patients with PS have a different prognosis, with a very high risk of developing acidosis, metabolic problems, and pancreatic dysfunction, and a shorter life expectancy than those with DBA. Here we present a patient who underwent HSCT for DBA but was subsequently diagnosed with PS after developing some complications. El síndrome de Pearson (SP) comparte varias características con la anemia de Diamond-Blackfan (ADB), incluida la anemia grave de inicio temprano, por lo que es importante hacer un diagnóstico diferencial. El diagnóstico diferencial de la ADB y el SP es fundamental, ya que los pacientes con ADB podrían responder al tratamiento con corticoesteroides, presentar remisión o beneficiarse del trasplante de células madre hematopoyéticas (TCMH). Sin embargo, los pacientes con SP tienen un pronóstico diferente, con un riesgo muy elevado de acidosis, problemas metabólicos y disfunción pancreática, y una expectativa de vida menor en comparación con aquellos con ADB. En este artículo, presentamos el caso de un paciente sometido a TCMH para la ADB, pero que luego fue diagnosticado con SP tras desarrollar algunas complicaciones.

Publicações recentes

Ver todas no PubMed

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Anemia de Diamond-Blackfan.

É de uma associação que acompanha esta doença? Fale com a gente →

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Anemia de Diamond-Blackfan e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

É uma anemia congênita aregenerativa e macrocítica rara, caracterizada pela falha da medula em produzir glóbulos vermelhos adequados (**eritroblastopenia**). Costuma se manifestar logo na infância ou no período neonatal com palidez e fadiga intensa.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

10 publicações do grafo RarasNet (PubMed) · 6 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. [Advances in bone marrow failure related ribosomopathies].
    Zhonghua er ke za zhi = Chinese journal of pediatrics2021PMID 34645224
  2. ORPHA:124
    Orphanet
  3. GARD:6274
    GARD (NIH)
  4. Q1208654
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (s.d.). Anemia de Diamond-Blackfan. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/anemia-de-diamond-blackfan

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Anemia de Diamond-Blackfan
Compêndio · Raras BR

Anemia de Diamond-Blackfan

ORPHA:124 · MONDO:0015253
Prevalência
Unknown
Herança
Autosomal dominant
CID-10
D61.0 · Anemia aplástica constitucional
CID-11
Ensaios
10 ativos
Medicamentos
9 registrados
Início
Childhood, Infancy, Neonatal
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0265265
Repurposing
11 candidatos
azacitidine — DNA methyltransferase inhibitor
cyanocobalamin — methylmalonyl CoA mutase stimulant|vitamin B
decitabine — glucocorticoid receptor agonist
+8 outros
EuropePMC
Wikidata
Papers 10a

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Indexação biomédica
fonte: MeSH (NLM)
Dado público estruturado
fonte: Wikidata
Moléculas estudadas na doença
fonte: OpenTargets
Rara